# Safety/Tolerability, Pharmacokinetics, and Pharmacodynamics of BIBB 1464 MS in Healthy Male Subjects, Combined With Preliminary Evaluation of Relative Bioavailability and Effect of Food

> **NCT02229838** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 73 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BIBB 1464 MS tablet
- **DRUG:** BIBB 1464 MS solution
- **DRUG:** BIBB 1464 MS placebo
- **OTHER:** Standard dinner

## Key facts

- **NCT ID:** NCT02229838
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-07
- **Primary completion:** 1999-09
- **Final completion:** —
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2014-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02229838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02229838, "Safety/Tolerability, Pharmacokinetics, and Pharmacodynamics of BIBB 1464 MS in Healthy Male Subjects, Combined With Preliminary Evaluation of Relative Bioavailability and Effect of Food". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02229838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*